Evidence map›Paper›PMID 34100160›Full record

ReviewClinical and experimental medicine2022

Sjögren's syndrome: a systemic autoimmune disease.

Simone Negrini, Giacomo Emmi, Monica Greco, Matteo Borro, Federica Sardanelli, Giuseppe Murdaca, Francesco Indiveri, Francesco Puppo

Registry-linked trialOpen access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Clinical and experimental medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06877546 (Photodynamic Treatment as Part of Oral Healthcare on Persons With Sjögren's Syndrome), which is not on this map. Cited by 280 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
280citing papers in PubMed, 7 pooled it
29.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06877546 naactive not recruitingnot on this mapstarted 2025, after this paper: background citation

Photodynamic Treatment as Part of Oral Healthcare on Persons With Sjögren's Syndrome

TypeinterventionalSponsorKoite Health OyRan2025 to 2025Enrolled16ConditionsSjogren Syndrome, XerostomiaArmsLumoral treatment
3 · Its place in the literature

Who cites it

280 citing papers in PubMed, 7 syntheses or guidelines pooled it, 417 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Guideline
  4. Pooled it
  5. Pooled it
  6. Guideline
  7. Pooled it
  8. Trial
  9. Article
  10. Article
  11. Article
  12. Article
  13. Observational
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article

220 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Simone NegriniDepartment of Internal Medicine, Clinical Immunology and Translational Medicine Unit, University of Genoa and IRCCS Ospedale Policlinico San Martino, Viale Benedetto XV, 6, 16132, Genoa, Italy. negrini@unige.it.ORCID http://orcid.org/0000-0003-1267-4320
Giacomo EmmiDepartment of Experimental and Clinical Medicine, University of Florence, 50134, Florence, Italy.
Monica GrecoDepartment of Internal Medicine, University of Genoa, 16132, Genoa, Italy.
Matteo BorroDepartment of Internal Medicine, University of Genoa, 16132, Genoa, Italy.
Federica SardanelliDepartment of Internal Medicine, University of Genoa, 16132, Genoa, Italy.
Giuseppe MurdacaDepartment of Internal Medicine, University of Genoa, 16132, Genoa, Italy.
Francesco IndiveriDepartment of Internal Medicine, University of Genoa, 16132, Genoa, Italy.
Francesco PuppoDepartment of Internal Medicine, University of Genoa, 16132, Genoa, Italy.
University of Genoa · ITOspedale Policlinico San Martino · ITUniversity of Florence · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sjögren's syndrome is a chronic autoimmune disease characterized by ocular and oral dryness resulting from lacrimal and salivary gland dysfunction. Besides, a variety of systemic manifestations may occur, involving virtually any organ system. As a result, the disease is characterized by pleomorphic clinical manifestations whose characteristics and severity may vary greatly from one patient to another. Sjögren's syndrome can be defined as primary or secondary, depending on whether it occurs alone or in association with other systemic autoimmune diseases, respectively. The pathogenesis of Sjögren's syndrome is still elusive, nevertheless, different, not mutually exclusive, models involving genetic and environmental factors have been proposed to explain its development. Anyhow, the emergence of aberrant autoreactive B-lymphocytes, conducting to autoantibody production and immune complex formation, seems to be crucial in the development of the disease. The diagnosis of Sjögren's syndrome is based on characteristic clinical signs and symptoms, as well as on specific tests including salivary gland histopathology and autoantibodies. Recently, new classification criteria and disease activity scores have been developed primarily for research purposes and they can also be useful tools in everyday clinical practice. Treatment of Sjögren's syndrome ranges from local and symptomatic therapies aimed to control dryness to systemic medications, including disease-modifying agents and biological drugs. The objective of this review paper is to summarize the recent literature on Sjögren's syndrome, starting from its pathogenesis to current therapeutic options.

Indexed as

Autoimmune DiseasesSjogren's SyndromeXerostomiaAutoantibodiesHumansSalivary GlandsAutoantibodiesLa/SSB antibodyRo/SSA antibodySjögren’s syndromeXerophthalmiaXerostomia

Identifiers

PMID34100160
PMCPMC8863725
OpenAlexW3171976197

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.